Argent Trust Co Has $29.08 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Argent Trust Co boosted its holdings in shares of Johnson & Johnson (NYSE:JNJFree Report) by 1.4% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 186,724 shares of the company’s stock after purchasing an additional 2,547 shares during the period. Johnson & Johnson accounts for approximately 1.6% of Argent Trust Co’s holdings, making the stock its 8th largest holding. Argent Trust Co’s holdings in Johnson & Johnson were worth $29,082,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. State Street Corp increased its holdings in shares of Johnson & Johnson by 1.1% in the second quarter. State Street Corp now owns 141,833,756 shares of the company’s stock valued at $23,476,323,000 after purchasing an additional 1,568,633 shares in the last quarter. Moneta Group Investment Advisors LLC increased its stake in shares of Johnson & Johnson by 90,144.4% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock valued at $9,607,414,000 after buying an additional 54,326,454 shares during the period. Geode Capital Management LLC raised its position in shares of Johnson & Johnson by 2.0% during the second quarter. Geode Capital Management LLC now owns 49,697,798 shares of the company’s stock worth $8,203,608,000 after acquiring an additional 990,298 shares during the last quarter. Morgan Stanley lifted its stake in shares of Johnson & Johnson by 12.0% during the fourth quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock valued at $7,458,962,000 after acquiring an additional 4,521,062 shares during the period. Finally, Capital International Investors boosted its holdings in Johnson & Johnson by 62.7% in the second quarter. Capital International Investors now owns 27,825,795 shares of the company’s stock valued at $4,605,627,000 after acquiring an additional 10,724,110 shares during the last quarter. Institutional investors and hedge funds own 68.40% of the company’s stock.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 59,397 shares of the business’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $156.27, for a total value of $9,281,969.19. Following the sale, the executive vice president now owns 141,416 shares in the company, valued at approximately $22,099,078.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.20% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

JNJ has been the topic of a number of research reports. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research report on Tuesday, February 6th. TheStreet cut shares of Johnson & Johnson from a “b” rating to a “c+” rating in a research note on Friday, November 17th. UBS Group raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $167.00 to $180.00 in a report on Friday, December 1st. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, February 6th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a report on Wednesday, January 24th. Eight research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $176.14.

Check Out Our Latest Report on JNJ

Johnson & Johnson Price Performance

Shares of JNJ opened at $157.87 on Tuesday. The stock has a 50 day simple moving average of $158.18 and a 200 day simple moving average of $158.62. Johnson & Johnson has a 52-week low of $144.95 and a 52-week high of $175.97. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.96 and a current ratio of 1.21. The firm has a market capitalization of $380.04 billion, a PE ratio of 11.43, a P/E/G ratio of 2.63 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJGet Free Report) last released its quarterly earnings results on Tuesday, January 23rd. The company reported $2.29 earnings per share for the quarter, beating the consensus estimate of $2.28 by $0.01. The company had revenue of $21.40 billion during the quarter, compared to analysts’ expectations of $21.02 billion. Johnson & Johnson had a net margin of 37.79% and a return on equity of 36.75%. The business’s quarterly revenue was down 9.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.35 earnings per share. Sell-side analysts predict that Johnson & Johnson will post 10.65 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 5th. Stockholders of record on Tuesday, February 20th will be given a dividend of $1.19 per share. The ex-dividend date is Friday, February 16th. This represents a $4.76 annualized dividend and a dividend yield of 3.02%. Johnson & Johnson’s dividend payout ratio is currently 34.47%.

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

Read More

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.